Pimasertib

DRUG9 trials

Sponsors

EMD Serono, Merck KGaA, Darmstadt, Germany, Sanofi, M.D. Anderson Cancer Center

Conditions

Advanced Solid TumorAdvanced Solid TumorsAnatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Hematologic NeoplasmsHematopoietic and Lymphoid Cell NeoplasmHepatocellular CarcinomaHormone Receptor Positive Breast Adenocarcinoma

Phase 1

Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer

CompletedNCT01016483

EMD SeronoPancreatic Adenocarcinoma

Start: 2009-11-30End: 2015-04-30Updated: 2017-07-13

MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)

TerminatedNCT01085331

EMD SeronoMetastatic Colorectal Cancer

Start: 2010-03-31End: 2012-04-30Updated: 2016-10-19

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

TerminatedNCT01378377

EMD SeronoAdvanced Solid Tumor

Start: 2011-05-27End: 2012-02-23Updated: 2018-07-30

A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy

TerminatedNCT01668017

Merck KGaA, Darmstadt, GermanyAdvanced Solid Tumors, Hepatocellular Carcinoma

Start: 2012-09-30End: 2015-05-31Updated: 2017-08-23

Oral Bioavailability and Mass Balance Trial With Pimasertib

CompletedNCT01713036

Merck KGaA, Darmstadt, GermanyLocally Advanced or Metastatic Solid Tumors

Start: 2012-11-30End: 2014-07-31Updated: 2017-08-15

A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients

CompletedNCT01985191

SanofiNeoplasm Malignant

Start: 2013-11-30End: 2016-02-29Updated: 2016-02-25

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

TerminatedNCT04789668

M.D. Anderson Cancer CenterAnatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm +11

Start: 2021-01-15End: 2023-12-08Updated: 2026-03-18

Phase 2

Trial of Pimasertib in Hematological Malignancies

TerminatedNCT00957580

EMD SeronoHematologic Neoplasms, Leukemia, Myeloid, Acute

Start: 2009-09-30End: 2012-12-31Updated: 2017-08-21

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

CompletedNCT01693068

EMD SeronoN-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma

Start: 2012-12-05End: 2016-10-24Updated: 2018-01-05

Related Papers

New advances in cancer therapy targeting TGF-β signaling pathways

Molecular Therapy — Oncolytics2023-12-0127 citations

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover

Cancers2020-06-2946 citations

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.

2018-12-2641 citations

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer

International Journal of Cancer2018-05-14100 citations

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.

2017-02-1322 citations

Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors.

2016-12-016 citations

Abstract 2603: Combination activity of the MEK inhibitor Pimasertib and the hypoxia-activated prodrug TH-302 in pancreatic and biliary tract tumor xenograft models

Cancer Research2015-08-01

Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.

Journal of Clinical Oncology2015-01-2021 citations

Absolute bioavailability, mass balance, elimination route, and metabolite profile of the selective oral MEK1/2 inhibitor pimasertib in cancer patients.

Journal of Clinical Oncology2014-05-201 citations